Quick Take: Tryp Therapeutics has partnered with Alcami Corporation to develop oral formulations for Tryp’s psilocybin active pharmaceutical ingredient. Tryp Therapeutics (CSE:TRYP), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO), to support the…